Euro RSCG Will Manage all Communication Activity for New Diabetes and Thrombosis Therapy Brands Through its Euro RSCG Life Global Healthcare Agency Group PARIS, November 16 /PRNewswire-FirstCall/ -- Sanofi-Aventis, a leading pharmaceutical company headquartered in France, has confirmed Euro RSCG Life as the global agency in charge of all communications for Lovenox/Clexane, the no 1 product for thrombosis treatment, and for Lantus and Apidra, market leading diabetes treatments. Sanofi-Aventis has also amplified its partnership with Euro RSCG Life by awarding the agency the responsibility of launching all communications programs for all new brands in these two therapeutic domains. Sanofi-Aventis has also awarded Euro RSCG C&O their Corporate Communications account, including internal editorial programs and publications. The Havas Group emphasizes that this success is the fruit of real international collaboration with all Euro RSCG Worldwide's teams in more than 40 countries. Sanofi-Aventis is Euro RSCG Worldwide's first global pharmaceutical client and this appointment demonstrates a significant increase in activity across the broad range of skills offered by Euro RSCG Worldwide- advertising, corporate communications, media relations, medical communication and interactive communication. About Havas Havas (Euronext Paris: HAV.PA) is a global advertising and communications services group. Headquartered in Paris, Havas operates through its two worldwide networks, Euro RSCG Worldwide headquartered in New York and Havas Media in Barcelona, and through Arnold Worldwide Partners. A multicultural and decentralized Group, Havas is present in more than 75 countries through its networks of agencies and contractual affiliations. The Group offers a broad range of communications services, including traditional advertising, direct marketing, media planning and buying, corporate communications, sales promotion, design, human resources, sports marketing, multimedia interactive communications and public relations. Havas employs approximately 14,400 people. Further information about Havas is available on the company's website: http://www.havas.com/ About Sanofi-Aventis The Sanofi-aventis Group is the world's 3rd largest pharmaceutical company, ranking number 1 in Europe. Backed by a world-class R&D organization, Sanofi-Aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine, vaccines. Contacts: Havas: Anne Marsan Tel: +33(0)1-58-47-90-33 Solenne Anthonioz Tel: +33(0)1-58-47-90-27 Euro RSCG Worldwide: Jonathan Sanchez Tel: +1-646-206-46-53 DATASOURCE: Havas CONTACT: Contacts: Havas: Anne Marsan, Tel: +33(0)1-58-47-90-33, , Solenne Anthonioz, Tel: +33(0)1-58-47-90-27, ; Euro RSCG Worldwide: Jonathan Sanchez, Tel: +1-646-206-46-53,

Copyright